Antropológiai-régészeti együttműködés a biológiai antropológiai maradványok roncsolásos mintavételének szabályozására

With the development of the new investigative techniques based on destructive or invasive sampling in biology and chemistry, a necessity to elaborate a sampling policy has emerged. As it is important to conduct research and at the same time to preserve specimens, our recommendation intends to help in deciding whether or not to grant permission for destructive sampling, bearing in mind the importance of the conservation of archaeological heritage and cultural goods (collectively “the elements of our cultural heritage”). In 2015 the Anthropological Interdisciplinary Scientific Committee (AISC), Section of Biological Sciences, Hungarian Academy of Sciences (SBS, HAS) appointed a working group to give recommendation for a Destructive Sampling Protocol for Biological Anthropological Remains. The Recommendation was drawn up by this working group, named “Committee for Preparation Destructive Sampling Protocol of Biological Anthropological Remains” of the AISC, SBS, HAS, with the contributions of physical anthropologists and archaeologists of several institutes and museums, and the members of the Archaeological Scientific Committee, HAS. The Recommendation was read and approved by the Committee of Anthropology, SBS, HAS and Archaeological Scientific Committee, HAS, in 2017

Evaluation of Persian Academy approved genetics terms acceptance in upper graduate user population

Finding Persian equivalents for scientific terms is one of the aims of Academy of Persian language and literature, and more than 50 scientific committees are now working on this scope in terminology department of the academy. Genetics and biotechnology terminology committee is one of these teams that started his activity from 2009 and since then approved more than 500 of these terms for use in academic fields. In this research 101 questionnaires including 20 questioned term were given to more than 101 upper graduate users including MSc and PhD students and academic staff of randomly selected universities in Tehran and Semnan provinces. And then the evaluation of their acceptance was carried out by a model given by Cooper for the Study of Language Spread. All 20 studied terms were randomly selected from genetic approved terms and divided in to two groups: newly coined equivalents (those equivalents that was newly coined by the committee) and selected equivalents (those that have the selected equivalent before).Results gathered and analyzed with statistical tests, and showed that most of accepted terms are among selected equivalents. By another words the newly coined terms has much less acceptability than the others. This research introduces a method for evaluation of approved Persian equivalents of scientific terms and besides show the state of some of these equivalents between user populations. The important point is that term selection for scientific terms including genetic terms; is not an obligatory rule, but is a proposal for meeting the researchers need to strength Persian language as a scientific language. And usage of these equivalents is completely on the part of researchers and students and their point of view to equivalents.

The Long-term Burden of COPD Exacerbations during Maintenance Therapy and Lung Function Decline

Data Sharing Statement The dataset supporting the conclusions of this article was derived from the Clinical Practice Research Datalink (www.cprd.com) and the Optimum Patient Care Research Database (www.opcrd.co.uk). The CPRD has broad National Research Ethics Service Committee (NRES) ethics approval for purely observational research using the primary care data and established data linkages. The OPCRD has ethical approval from the National Health Service (NHS) Research Authority to hold and process anonymized research data (Research Ethics Committee reference: 15/EM/0150). This study was approved by the Anonymized Data Ethics Protocols and Transparency (ADEPT) committee – the independent scientific advisory committee for the OPCRD, and the Independent Scientific Advisory Committee (ISAC) for the CPRD. The authors do not have permission to give public access to the study dataset; researchers may request access to CPRD or OPCRD data for their own purposes. Access to CPRD can be made via the CPRD website (https://www.cprd.com/researcher/) or via the inquiries email [email protected]. Access to OCPRD can be made via the OCPRD website (https://opcrd.co.uk/our-database/data-requests/) or via the inquiries email [email protected]. Funding This study is funded by AstraZeneca. AstraZeneca participated in the study design and reporting.Peer reviewedPublisher PD

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care

This study was supported by funding from BGP Products Operations GmbH (A MylanCompany). BGP Products Operations GmbH was given the opportunity to review the manuscript for medical and scientific accuracy as well as for intellectual property considerations. The dataset supporting the conclusions of this article was derived from the Optimum Patient Care Research Database (www.opcrd.co.uk). The OPCRD has ethical approval from the National Health Service (NHS) Research Authority to hold and process anonymized research data (Research Ethics Committee reference: 15/EM/0150). This study was approved by the Anonymized Data Ethics Protocols and Transparency (ADEPT) committee – the independent scientific advisory committee for the OPCRD. The authors do not have permission to give public access to the study dataset; researchers may request access to OPCRD data for their own purposes. Access to OCPRD can be made via the OCPRD website (https://opcrd.co.uk/our-database/data-requests/) or via the enquiries email [email protected] reviewedPublisher PD

ISAC Protocol 19_129 - Common infections and incident dementia: a historical cohort study using UK primary and secondary care data

Study protocol approved by the Independent Scientific Advisory Committee (ISAC) of the Medicines Healthcare regulatory agency in June 2019

Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD : A Historical Real-World Non-Inferiority Study

Acknowledgments: Dave Singh is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre (BRC). Writing and editorial support was provided by Dr Julia Granerod, supported by the Observational and Pragmatic Research Institute Pte. Ltd (OPRI). Data Sharing Statement The dataset supporting the conclusions of this article was derived from the Optimum Patient Care Research Database (www.opcrd.co.uk). The OPCRD has ethical approval from the National Health Service (NHS) Research Authority to hold and process anonymised research data (Research Ethics Committee reference: 15/EM/0150). This study was approved by the Anonymised Data Ethics Protocols and Transparency (ADEPT) committee – the independent scientific advisory committee for the OPCRD. The authors do not have permission to give public access to the study dataset; researchers may request access to OPCRD data for their own purposes. Access to OCPRD can be made via the OCPRD website (https://opcrd.co.uk/our-database/data-requests/) or via the enquiries email [email protected] reviewedPublisher PD

Protocol for a randomised control trial of methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients (MOTION)

Gastrointestinal dysmotility and constipation are common problems in intensive care patients. The majority of critical care patients are sedated with opioids to facilitate tolerance of endotracheal tubes and mechanical ventilation, which inhibit gastrointestinal motility and lead to adverse outcomes. Methylnaltrexone is a peripheral opioid antagonist that does not cross the blood-brain barrier and can reverse the peripheral side effects of opioids without affecting the desired central properties. This trial will investigate whether methylnaltrexone can reverse opioid-induced constipation and gastrointestinal dysmotility.This is a single-centre, multisite, double-blind, randomised, placebo-controlled trial. 84 patients will be recruited from 4 intensive care units (ICUs) within Imperial College Healthcare NHS Trust. Patients will receive intravenous methylnaltrexone or placebo on a daily basis if they are receiving opioid infusion to facilitate mechanical ventilation and have not opened their bowels for 48 hours. All patients will receive standard laxatives as per the clinical ICU bowel protocol prior to randomisation. The primary outcome of the trial will be time to significant rescue-free laxation following randomisation. Secondary outcomes will include tolerance of enteral feed, gastric residual volumes, incidence of pneumonia, blood stream and Clostridium difficile infection, and any reversal of central opioid effects.The trial protocol, the patient/legal representative information sheets and consent forms have been reviewed and approved by the Harrow Research Ethics Committee (REC Reference 14/LO/2004). An independent Trial Steering Committee and Data Monitoring Committee are in place, with patient representation. On completion, the trial results will be published in peer-reviewed journals and presented at national and international scientific meetings.2014-004687-37; Pre-results

Association between COPD exacerbations and lung function decline during maintenance therapy

Acknowledgements: Writing and editorial support was provided by Dr Julia Granerod, supported by the Observational and Pragmatic Research Institute Pte. Ltd (OPRI). Funding: This study was funded by AstraZeneca.Data availability statement: Data may be obtained from a third party and are not publicly available. The dataset supporting the conclusions of this article was derived from the Clinical Practice Research Datalink (www.cprd.com) and the Optimum Patient Care Research Database (www.opcrd.co.uk). The CPRD has broad National Research Ethics Service Committee (NRES) ethics approval for purely observational research using the primary care data and established data linkages. The OPCRD has ethical approval from the National Health Service (NHS) Research Authority to hold and process anonymised research data (Research Ethics Committee reference: 5/EM/0150). This study was approved by the Anonymised Data Ethics Protocols and Transparency (ADEPT) committee – the independent scientific advisory committee for the OPCRD, and the Independent Scientific Advisory Committee (ISAC) for the CPRD. The authors do not have permission to give public access to the study dataset; researchers may request access to CPRD or OPCRD data for their own purposes. Access to CPRD can be made via the CPRD website (https://www.cprd.com/researcher/) or via the enquiries email enquiries@cprd. com. Access to OCPRD can be made via the OCPRD website(https://opcrd.co.uk/our-database/data-requests/) or via the enquiries email [email protected]. The study was designed, implemented, and registered in accordance with the criteria of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (EUPAS19879).Peer reviewedPublisher PD

Physics Projects for a Future CERN-LNGS Neutrino Programme

We present an overview of the future projects concerning the neutrino oscillation physics in Europe. Recently a joint CERN-LNGS scientific committee has reviewed several proposals both for the study of atmospheric neutrinos and for long (LBL) and short baseline (SBL) neutrino oscillation experiments. The committee has indicated the priority that the European high energy physics community should follows in the field of neutrino physics, namely a new massive, atmospheric neutrino detector and a nu_tau appearance campaign exploiting the new CERN-LNGS Neutrino Facility (NGS), freshly approved by CERN and INFN. The sensitivity and the discovery potential of the whole experimental program in the Super-Kamiokande allowed region are discussed.Comment: 11 pages, 4 figures, to appear in the Proceedings of the XVIII International Conference on Neutrino Physics and Astrphysics, Takayama, Japan, 199